Congress Materials – European Chron's and Colitis Organization (ECCO 2025)
2025 European Chron's and Colitis Organization | Feb 19-22 | Berlin, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Baseline characteristics and nutrition in patients with moderately to severely active inflammatory bowel disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials
E. De Greef, É. Kosaras, N. Béres, S. Cohen, L. Conklin, R. Strauss, B. Godwin, P. Ufberg, L. Damaraju, R. Zhang, S. Volger, L. Kim, E. Van Limbergen
Comparison of pharmacodynamic and mechanistic response of guselkumab subcutaneous and intravenous induction in moderately to severely active Crohn’s disease: molecular analysis of the GRAVITI and GALAXI Phase 3 studies
Dylan Richards, Ruchi Patel, Klebea Sohn, Amy Hart, Tae Lee, Jared Liu, Christopher Sisk, Mobolaji Olurinde, Natalie A. Terry, Bradford McRae, Walter Reinisch, Brian Feagan, Flavio Steinwurz, Remo Panaccione, Geert D’Haens, and Patrick Branigan
Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GALAXI 2/3 results through week 48
Julian Panés, Tadakuzu Hisamatsu, Alessandro Armuzzi, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Kitty YY Wan, Zijiang Yang, Scott Pin, Bruce E. Sands, David T. Rubin
Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 48
A. Hart, R. Panaccione, F. Steinwurz, Q. Cao, T. Hisamatsu, S. Nancey, M. Olurinde, Z. Yang, E. Merrall, N.A. Terry, B.E. Sands
Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
Anita Afzali, David T. Rubin, Silvio Danese, Yaser Rayyan, Minhu Chen, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Mario Gomez, Kitty Yuen Yi Wan, Zijiang Yang, Bruce E. Sands, Geert D’Haens
Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through Week 48 from the phase 3 GRAVITI study
Ailsa Hart, Remo Panaccione, Flavio Steinwurz, Silvio Danese, Tadakazu Hisamatsu, Qian Cao, Mobolaji Olurinde, Marion L. Vetter, Zijiang Yang, Yuhua Wang, Jewel Johanns, Natalie A. Terry, Bruce E. Sands, Geert D’Haens
Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study
Laurent Peyrin-Biroulet, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Silke Jörgens, Lingjing Jiang, Hongyan Zhang, Tadakazu Hisamatsu, David T. Rubin, Millie Long
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: Subgroup analysis of the Phase 3 GRAVITI study
W. Liu, H. Guo, T.O. Kim, K. Takeuchi, T. Hisamatsu, J. Fable, M. Olurinde, B. Wahking, J. Zhuo, Q. Cao
Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn’s disease and inadequate response to ustekinumab: Phase 2 GALAXI 1 study long-term extension results
A. Afzali, D. Wolf, R. Leong, L. Salese, L. Gao, C. Busse, J. Panés
Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results at Week 12 from the phase 3 GRAVITI study
G. D’Haens, T. Hisamatsu, F. Steinwurz, A. Hart, W. Liu, M. Olurinde, P. Ngqawa, Z. Yang, E. Merrall, N.A. Terry, B.E. Sands, R. Panaccione
Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn’s disease: Results at Week 12 from the phase 3 GRAVITI study
A. Hart, T. Hisamatsu, F. Steinwurz, G. D’Haens, W. Liu, M. Olurinde, P. Ngqawa, Z. Yang, E. Merrall, N.A. Terry, R. Panaccione, B.E. Sands
Guselkumab Efficacy and Safety in East Asian Participants with Moderate to Severely Active Crohn’s Disease: Subgroup Analysis of the GALAXI 2 & 3 Phase 3 Studies
H Nakase, B Chen, Q Cao, K Matsuoka, T Hisamatsu, DI Park, B Wahking, WC Yiu, J Zhuo, M Chen
Guselkumab efficacy and safety in East Asian participants with moderate to severely active ulcerative colitis: Subgroup analysis of the Phase 2b/3 QUASAR induction and maintenance studies
B Chen, BD Ye, Q Cao, F Hirai, M Saruta, M Chen, S Pelak, N Shipitofsky, B Wahking, J Zhuo, T Hisamatsu
Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study
B.E. Sands, S. Danese, Q. Cao, F. Steinwurz, J. Kierkus, C. Han, M. Olurinde, Z. Yang, E. Merrall, N.A. Terry, A. Hart
Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active ulcerative colitis: Results from the Phase 3 QUASAR induction study
Sunandini Sridhar, Amy Hart, Swati Venkat, Kuan-Hsiang Gary Huang, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, David Rubin, Axel Dignass, Daniel Cua, Tom Freeman, Dawn Waterworth, Bradford McRae, Bram Verstockt and Patrick Branigan
Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with moderately to severely ulcerative colitis
Amy Hart, Sunandini Sridhar, Swati Venkat, Kuan-Hsiang Gary Huang, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, David T. Rubin, Axel Dignass, Daniel Cua, Tom Freeman, Dawn Waterworth, Bradford McRae, Bram Verstockt, Patrick Branigan
Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active ulcerative colitis: phase 3 QUASAR maintenance study
B. Bressler, L. Peyrin-Biroulet, W. Afif, M.A. Samaan, S-C. Wei, S. Yarandi, M. Germinaro, P. Mistry, C. Han, J.R. Allegretti, G.R. Lichtenstein
LOW REMISSION RECAPTURE AFTER USTEKINUMAB DOSE OPTIMIZATION IN CROHN’S DISEASE: RESULTS OF THE RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND REScUE STUDY.
Peter Bossuyt, Jean-Francois Rahier, Filip Baert, Edouard Louis, Elisabeth Macken, Triana Lobaton, Julie Busschaert, Harald Peeters, Pieter Dewint, Denis Franchimont, Joris Dutré, Barbara Willandt, Christophe Claessens, Olivier Dewit, Marc Ferrante, Séverine Vermeire
Predicting disease remission in ulcerative colitis patients – early results from the PRESAGER study
Rie Louise Møller Nordestgaard, Bobby Lo, Rosalina Bergstrøm, Izabella Adzioski, Helene Skotte Nielsen, Ida Marie Hawwa, Signe Krogsgaard Holme, Bermal Tiftikci, Katarzyna Majchrzak, Ida Vind, Flemming Bendtsen, Johan Burisch
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
B.E. Sands, R. Panaccione, S. Danese, J. Panés, T. Hisamatsu, G. D’Haens, R. Van Rampelbergh, M. Olurinde, J. Yee, T. Baker, S. Yarandi, M. Germinaro, M.L. Vetter, H. Li, M. Rosas Ballina, J.R. Allegretti, A. Afzali, D.T. Rubin
Safety of intravenous and subcutaneous guselkumab induction administration: results from the GALAXI and GRAVITI studies in participants with Crohn’s disease
S. Danese, B.E. Sands, A. Afzali, T. Hisamatsu, A. Armuzzi, D. Wolf, G. Duvall, R. Van Rampelbergh, M. Olurinde, N.A. Terry, J. Yee, H. Li, M. Rosas Ballina, G. D’Haens, D.T. Rubin, R. Panaccione
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.